Genelux (NASDAQ:GNLX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright also issued estimates for Genelux's Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at $1.32 EPS.
Genelux Stock Performance
GNLX stock traded down $0.09 during mid-day trading on Monday, reaching $2.41. The company had a trading volume of 120,469 shares, compared to its average volume of 206,801. Genelux has a fifty-two week low of $1.60 and a fifty-two week high of $5.89. The company has a market capitalization of $83.69 million, a price-to-earnings ratio of -2.54 and a beta of -1.41. The firm has a fifty day simple moving average of $4.03 and a 200 day simple moving average of $3.10.
Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09). As a group, analysts predict that Genelux will post -0.88 earnings per share for the current year.
Institutional Investors Weigh In On Genelux
Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in shares of Genelux during the 4th quarter worth approximately $25,000. Apollon Wealth Management LLC grew its position in shares of Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after acquiring an additional 2,857 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Genelux in the 4th quarter valued at $41,000. D.A. Davidson & CO. purchased a new stake in Genelux in the 4th quarter valued at $51,000. Finally, XTX Topco Ltd purchased a new position in Genelux during the 3rd quarter worth $59,000. Hedge funds and other institutional investors own 37.33% of the company's stock.
About Genelux
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
